focus -WSS

focus

author：fashion 2025-09-06 01:58:31 - browse：6

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Study on Amgen’s bispecific immunotherapy produces positive data

knowledge

WSS

Merck, Daiichi strike cancer drug pact worth up to $22 billion

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Readout: Friday, Oct. 20 biotech updates

For AI in health care standards, federal regulators join with industry group

Roche acquires Telavant from Roivant, adding experimental IBD treatment

knowledge

focus

focus

BioMarin wins approval for gene therapy to treat hemophilia A

He's 19 months old and has one of the world’s rarest diseases

Sports medicine is finally prioritizing gender equality

FDA clears Verve to begin U.S. study of gene

Medical leaders decry Supreme Court decision on affirmative action

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Apple is now the first public company to be valued at $3 trillion

Why a market frenzy over new weight loss drugs defies logic

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: How researchers deal with rejection

entertainment

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Immune cells and nerve overgrowth may explain recurring UTI pain

Ozempic has benefits for kidney disease as well as diabetes

For AI in health care standards, federal regulators join with industry group

Stem cell biologist probes earliest stages of human development

UnitedHealth, Optum discontinue NaviHealth name

focus

hotspot

knowledge

leisure time